- Oops!Something went wrong.Please try again later.
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2020 financial results on Thursday, April 30, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Thursday, April 30, 2020
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
Telephone 888-220-8474 (domestic) or +1 720-452-9217 (international); conference ID 7835915
Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, April 30, 2020 through 5:00 p.m. PT on Sunday, May 3, 2020 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7835915
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200413005032/en/